
Xanomeline/Trospium Mechanism of Action, Efficacy, and Safety
Panelists discuss how the muscarinic pathway of xanomeline/trospium offers a safer, nondopaminergic approach to schizophrenia care.
Episodes in this series

Panelists discuss how xanomeline/trospium chloride introduces a paradigm shift in schizophrenia therapy through selective muscarinic receptor activity, avoiding dopamine blockade.
Panelists discuss how phase 3 EMERGENT-2 and EMERGENT-3 trials demonstrated its efficacy in reducing psychotic symptoms with minimal metabolic or neurologic adverse effects.
Panelists discuss how this mechanism may redefine treatment options for patients who experience poor tolerability or limited response to existing dopamine-based therapies.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.





























































